CLL – Medxy AI

Fixed-Duration Therapy Challenging the Continuous Paradigm in Chronic Lymphocytic Leukemia: Insights from the CLL17 Trial

By MedXY 12/19/2025

The Phase 3 CLL17 trial demonstrates that fixed-duration venetoclax-based regimens are noninferior to continuous ibrutinib in previously untreated CLL, offering deep molecular responses and comparable progression-free survival while allowing for treatment-free intervals.

Hematology-Oncology news Oncology

Pirtobrutinib Matches and May Surpass Ibrutinib in BTKi‑Naïve CLL/SLL: First Randomized Head‑to‑Head Results with Improved Cardiac Safety

By MedXY 12/07/2025

In the first randomized comparison of pirtobrutinib versus ibrutinib in BTKi‑naïve CLL/SLL (N=662), pirtobrutinib met noninferiority for overall response and showed favorable early PFS trends and lower rates of atrial fibrillation and hypertension.

Hematology-Oncology news

Venetoclax Dose Escalation Triggers a Rapid BAFF–BCL-2 Survival Axis in CLL: Implications for Resistance and Combination Strategies

By MedXY 11/17/2025

Early venetoclax therapy rapidly induces a BAFF-driven upregulation of prosurvival BCL-2 family proteins in surviving CLL cells, suggesting homeostatic cytokine signaling limits depth and durability of response and identifying BAFF/MCL-1 pathways as candidate co-targets.

Hematology-Oncology news

Venetoclax‑Obinutuzumab in First‑Line CLL: Efficacy Preserved in Unfit Patients — but Dose Intensity Matters

By MedXY 11/15/2025

Large trial and real‑world data show fixed‑duration venetoclax‑obinutuzumab delivers high response and durable PFS in fit and unfit CLL patients; maintaining adequate venetoclax dose intensity appears important for MRD and long‑term outcomes.

Clinical Updates Hematology-Oncology news Specialties

Pirtobrutinib Demonstrates Superior Efficacy and Tolerability in cBTKi-Pretreated CLL/SLL: Insights from the BRUIN CLL-321 Phase III Trial

By MedXY 08/01/2025

Pirtobrutinib significantly improves progression-free survival and tolerability over standard regimens in covalent BTK inhibitor-pretreated CLL/SLL, offering a promising new option for this challenging population.